Dr. Ryan Wylie
Department of Chemistry and Chemical Biology,
The clinical efficacy of immunotherapeutics against many solid tumors remains elusive in part due to poor tumor uptake, lack of adaptive responses and the therapy-suppressive tumor microenvironment (TME). Our lab is developing platform technologies to improve efficacy by optimizing local T cell engagers therapies. To improve T engaging therapies against solid tumors, we are investigating intratumoral platform technologies to increase the residence time of T cell engagers by: (1) the sustained release of BiTEs; and, (2) polymer antibody conjugates for modular T cell engagers (MoTEs). Injectable zwitterionic hydrogels incorporating displacement affinity release were developed to achieve tunable and long term release of the protein-based CD133 targeting BiTEs for extended cytotoxicity against CD133+ cancer cells. We also established MoTEs to further extend the duration of action by reducing clearance rates compared to traditional BiTE structures. Moreover, the MoTE scaffold may prove beneficial for targeting tumor heterogeneity through the incorporation of synthetic and exchangeable cancer targeting ligands (CTLs). Therefore, the reconsideration of delivery strategies and therapeutic scaffolds can enhance local T cell engaging therapies
Dr. Ryan Wylie received his Ph.D. in Chemistry at the University of Toronto under the supervision of Prof. Molly Shoichet studying the biochemical patterning of hydrogels. Dr. Wylie was a Banting Postdoctoral Fellow with Profs. Daniel Kohane at Harvard Medical School and Robert Langer at the MIT developing drug delivery strategies and anti-angiogenic therapies for retinal diseases, as well as blood filtration devices for the treatment of sepsis. Currently, Dr. Wylie is an Associate Professor in the Department of Chemistry and Chemical Biology at McMaster focusing on polymeric coatings for medical implants and sensors, and biomaterials for immune modulation.